Targeting Tumors with Humanized Antibodies
Author Information
Author(s): Casey J L, Napier M P, King D J, Pedley R B, Chaplin L C, Weir N, Skelton L, Green A J, Hope-Stone L D, Yarranton G T, Begent R H J
Primary Institution: Cancer Research UK Targeting and Imaging Group, Department of Oncology, Royal Free and University College Medical School, University College London
Hypothesis
Can a humanized divalent-Fab′ antibody fragment effectively target tumors in patients with colorectal cancer?
Conclusion
The study demonstrated that the humanized divalent-Fab′ maleimide can effectively target tumors and has lower immunogenicity compared to murine antibodies.
Supporting Evidence
- Eight out of ten patients showed positive tumor images.
- One previously undetected lesion was identified during imaging.
- The new antibody showed a higher tumor to blood ratio compared to previous treatments.
Takeaway
This study tested a new type of antibody that can find and target cancer cells better, helping doctors see where the cancer is in the body.
Methodology
Ten patients with colorectal cancer received an injection of iodine-131-labelled humanized divalent-Fab′ maleimide, and imaging was performed to assess tumor localization.
Potential Biases
Potential bias due to the open-label design of the trial.
Limitations
The study had a small sample size and was limited to a single center.
Participant Demographics
Patients with colorectal cancer, including those with metastatic or recurrent disease.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website